This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Richard C. Becker, MD; Joseph S. Alpert, MD
Worcester, Mass

Arch Intern Med. 1991;151(10):2100.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply. —

Watson raises an interesting and clinically relevant question concerning the use of 1-desamino-8D-arginine vasopressin (DDAVP) in patients with hemorrhagic disorders and coronary artery disease.

Intravenous DDAVP administration increases antihemophilic factor (factor VIII) titers in plasma. Given in a standard dose of 0.3 µg/kg, it also provokes a modest rise in factor VII and factor XII concentrations. These properties may, therefore, be considered procoagulant, favoring normal hemostasis.

Coronary arterial and other thrombotic events in patients with hemophilia have typically occurred following the intravenous administration of factor VIII concentrate.^1,2 Indeed, the case cited³ describes an elderly man with coronary disease risk factors who experienced a myocardial infarction following peripheral vascular surgery. Beyond the fact that coronary disease is highly prevalent in these patients and myocardial infarction is the leading cause of perioperative morbidity and mortality,⁴ the patient received factor VIII concentrate in addition to DDAVP, the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?